echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > PacBio will acquire Omniome, a developer of short-read long sequencing, for US$800 million

    PacBio will acquire Omniome, a developer of short-read long sequencing, for US$800 million

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pacific Biosciences said on Tuesday that it has signed a definitive agreement to acquire Omniome, a developer of short-read sequencing technology, for up to $800 million


    According to the terms of the agreement, PacBio will acquire Omniome for 9.


    Omniome, headquartered in San Diego, develops a highly differentiated proprietary short-read sequencing platform that can provide excellent accuracy


    The integration of these complementary technologies will promote PacBio to expand its sequencing market opportunities in novel ways and provide customers with more value in a wider range of applications


    Christian Henry, CEO of PacBio, said: "Adding Omniome's short-read sequencing technology to our long-read product portfolio will not only expand our overall market opportunities, but we believe it will further accelerate the adoption of SMRT sequencing because We are expected to attract more customers through deeper product offerings


    "The reason why Omniome was chosen is because of its novel method.


    In addition, PacBio also said that it will expand its cooperation with Invitae to develop a production-scale HiFi sequencing platform, which is expected to include technology from Omniome


    Sean George, CEO and co-founder of Invitae, said: "By combining SBB sequencing with PacBio's HiFi sequencing, next-generation sequencing opportunities can be extended to patients in a clinical setting while improving accuracy and reducing costs


    Richard Shen, President of Omniome, said: "We developed (SBB) this chemical method because clinical applications require accuracy that is difficult to achieve with current sequencing technologies


    Once PacBio's acquisition of Omniome is completed, the expansion of PacBio's cooperation with Invitae is expected to begin in the second half of 2021



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.